MiNK Therapeutics, Inc. Common Stock

INKTNASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
11.64 USD
↗ 0.33 (2.92%)AT CLOSE (11:59 AM EDT)
12.30
↗ 0.66 (5.65%)
POST MARKET (AS OF 07:52 PM EDT)
Post Market
AS OF 07:52 PM EDT
12.30
↗ 0.66 (5.65%)
🔴Market: CLOSED

MiNK Therapeutics, Inc. Common Stock (INKT) trades at $11.64 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (98.3%) and a bearish Death Cross on the long-term moving averages.

Technical & fundamental data as of Jun 26, 2026.

Open?$11.52
High?$11.97
Low?$11.10
Prev. Close?$11.31
Volume?34.6K
Avg. Volume?40.7K
VWAP?$11.61
Rel. Volume?0.85x
Bid / Ask
Bid?$10.80 × 100
Ask?$14.00 × 400
Spread?$3.20
Midpoint?$12.40
Valuation & Ratios
Market Cap?58.0M
Shares Out?5.0M
Float?1.2M
Float %?24.8%
P/E Ratio?N/A
P/B Ratio?-4.57
EPS?-$2.50
Dividend?0.00%
Ex-Dividend?N/A
RelatedFTFT
News
Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
15
Market Cap
56.3M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.minktherapeutics.com
Listed
2021-10-15
Address
149 FIFTH AVENUE
NEW YORK, NY 10010
Phone: 212-994-8250
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
46
Piotroski F-Score?0/9Weak
Altman Z-Score?-23.76Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.95%Elevated
Short Interest?115.8K
Days to Cover?2.7
Free Float1.2M
Avg Daily Volume42.4K
Settlement Date2026-06-15
Financial Health
Current Ratio?1.38Adequate
Quick Ratio?1.38Adequate
Cash Ratio?1.31Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
-4.57CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
97
98.3%STRONG▾
ROA?
S&P
3
-120.2%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$48.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist